Edition:
United Kingdom

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

10.35USD
15 Dec 2017
Change (% chg)

$0.17 (+1.67%)
Prev Close
$10.18
Open
$10.19
Day's High
$10.47
Day's Low
$10.19
Volume
336,399
Avg. Vol
56,593
52-wk High
$54.70
52-wk Low
$10.06

Select another date:

Fri, Dec 15 2017

BRIEF-Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln

* MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text :[http://bit.ly/2yGsbJv] Further company coverage:

BRIEF-Merrimack reports Q3 loss per share from continuing operations $0.40

* Merrimack Pharmaceuticals Inc - Qtrly loss per share from continuing operations $0.40

BRIEF-Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer

* Merrimack receives orphan drug designation for MM-121 for the treatment of heregulin positive non-small cell lung cancer

BRIEF-Merrimack commences tender offer for outstanding 4.50 pct convertible senior notes

* Merrimack commences tender offer for any and all of its outstanding 4.50 pct convertible senior notes due 2020

BRIEF-Merrimack announces settlement of convertible note litigation

* Merrimack announces settlement of convertible note litigation

BRIEF-Merrimack announces date of one-for-ten reverse stock split

* Merrimack announces date of one-for-ten reverse stock split

BRIEF-Merrimack Pharmaceuticals names Jean Franchi CFO

* Merrimack Pharmaceuticals Inc - ‍appointment of Jean M. Franchi as chief financial officer, effective August 21, 2017​ Source text for Eikon: Further company coverage:

BRIEF-Merrimack reports Q2 loss per share $0.22

* Merrimack - continues to believe cash, cash equivalents as of june 30, potential milestone payments, to be sufficient to fund operations into H2 2019​ Source text for Eikon: Further company coverage:

BRIEF-Merrimack appoints Thomas Needham as chief business officer

* Merrimack appoints Thomas Needham as chief business officer Source text for Eikon: Further company coverage:

BRIEF-Merrimack announces completion of enrollment in phase 2 carrie study of mm-141

* Merrimack announces completion of enrollment in phase 2 carrie study of mm-141; data expected in first half of 2018 Source text for Eikon: Further company coverage:

Select another date: